You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePraziquantel
Accession NumberDB01058  (APRD01196, EXPT02728)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionAn anthelmintic used in most schistosome and many cestode infestations. [PubChem]
Structure
Thumb
Synonyms
Biltricide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BiltricideTablet, film coated600 mg/1OralBayer Health Care Pharmaceuticals Inc.2011-04-21Not applicableUs
BiltricideTablet600 mgOralBayer Inc1997-04-24Not applicableCanada
BiltricideTablet, film coated600 mg/1OralDepartment Of State Health Services, Pharmacy Branch2016-11-18Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6490C9U457
CAS number55268-74-1
WeightAverage: 312.4061
Monoisotopic: 312.183778022
Chemical FormulaC19H24N2O2
InChI KeyFSVJFNAIGNNGKK-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
IUPAC Name
2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino[2,1-a]isoquinolin-4-one
SMILES
O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1
Pharmacology
IndicationFor the treatment of infections due to all species of schistosoma.
Structured Indications
PharmacodynamicsPraziquantel is an anthelmintic used in most schistosome and many cestode infestations. Praziquantel effects the permeability of the cell membrane resulting in the contraction of schistosomes. The drug further causes vacuolization and disintegration of the schistosome tegument. The effect is more marked on adult worms compared to young worms. An increased calcium influx may play an important role. Secondary effects are inhibition of glucose uptake, lowering of glycogen levels and stimulation of lactate release. The action of praziquantel is limited very specifically to trematodes and cestodes; nematodes (including filariae) are not affected.
Mechanism of actionPraziquantel works by causing severe spasms and paralysis of the worms' muscles. This paralysis is accompanied - and probably caused - by a rapid Ca 2+ influx inside the schistosome. Morphological alterations are another early effect of praziquantel. These morphological alterations are accompanied by an increased exposure of schistosome antigens at the parasite surface. The worms are then either completely destroyed in the intestine or passed in the stool. An interesting quirk of praziquantel is that it is relatively ineffective against juvenile schistosomes. While initially effective, effectiveness against schistosomes decreases until it reaches a minimum at 3-4 weeks. Effectiveness then increases again until it is once again fully effective at 6-7 weeks. Glutathione S-transferase (GST), an essential detoxification enzyme in parasitic helminths, is a major vaccine target and a drug target against schistosomiasis. Schistosome calcium ion channels are currently the only known target of praziquantel.
TargetKindPharmacological actionActionsOrganismUniProt ID
Schistosome calcium ion (Ca2+) channelsGroupyes
other/unknown
Schistosomanot applicabledetails
Related Articles
AbsorptionRapidly absorbed (80%)
Volume of distributionNot Available
Protein binding80 to 85%
Metabolism

renal

Route of eliminationNot Available
Half life0.8-1.5 hours (in serum)
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Praziquantel can be increased when it is combined with Abiraterone.Approved
AmiodaroneThe metabolism of Praziquantel can be decreased when combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Praziquantel can be decreased when it is combined with Amodiaquine.Approved
AprepitantThe serum concentration of Praziquantel can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Praziquantel.Approved, Investigational
ArmodafinilThe metabolism of Praziquantel can be decreased when combined with Armodafinil.Approved, Investigational
AtazanavirThe metabolism of Praziquantel can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Praziquantel can be decreased when combined with Atomoxetine.Approved
AzithromycinThe metabolism of Praziquantel can be decreased when combined with Azithromycin.Approved
BexaroteneThe serum concentration of Praziquantel can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Praziquantel can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Praziquantel can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Praziquantel can be decreased when it is combined with Bosentan.Approved, Investigational
CaffeineThe metabolism of Praziquantel can be decreased when combined with Caffeine.Approved
CarbamazepineThe serum concentration of Praziquantel can be decreased when it is combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Praziquantel can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Praziquantel can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Praziquantel can be decreased when it is combined with Chloroquine.Approved, Vet Approved
CholecalciferolThe metabolism of Praziquantel can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Praziquantel can be increased when it is combined with Cimetidine.Approved
CitalopramThe metabolism of Praziquantel can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Praziquantel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Praziquantel can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Praziquantel can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Praziquantel can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Praziquantel can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Praziquantel can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Praziquantel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Praziquantel can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Praziquantel can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Praziquantel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Praziquantel can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Praziquantel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Praziquantel can be decreased when combined with Delavirdine.Approved
DexamethasoneThe serum concentration of Praziquantel can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DihydroergotamineThe metabolism of Praziquantel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Praziquantel can be decreased when combined with Diltiazem.Approved
DoxycyclineThe metabolism of Praziquantel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Praziquantel can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Praziquantel can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Praziquantel can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Praziquantel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Praziquantel can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Praziquantel can be decreased when combined with Esomeprazole.Approved, Investigational
EtravirineThe serum concentration of Praziquantel can be decreased when it is combined with Etravirine.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Praziquantel.Approved
FluconazoleThe metabolism of Praziquantel can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Praziquantel can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Praziquantel can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Praziquantel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Praziquantel can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Praziquantel can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Praziquantel can be increased when it is combined with Fusidic Acid.Approved
GemfibrozilThe metabolism of Praziquantel can be decreased when combined with Gemfibrozil.Approved
HydroxychloroquineThe serum concentration of Praziquantel can be decreased when it is combined with Hydroxychloroquine.Approved
IdelalisibThe serum concentration of Praziquantel can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Praziquantel can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Praziquantel can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Praziquantel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Praziquantel can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Praziquantel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Praziquantel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Praziquantel can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Praziquantel can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Praziquantel can be decreased when combined with Ketoconazole.Approved, Investigational
LidocaineThe metabolism of Praziquantel can be decreased when combined with Lidocaine.Approved, Vet Approved
LopinavirThe metabolism of Praziquantel can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Praziquantel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Praziquantel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Praziquantel can be decreased when it is combined with Lumacaftor.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Praziquantel.Approved, Investigational
MexiletineThe metabolism of Praziquantel can be decreased when combined with Mexiletine.Approved
MifepristoneThe serum concentration of Praziquantel can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Praziquantel can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Praziquantel can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Praziquantel can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Praziquantel can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe metabolism of Praziquantel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Praziquantel can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Praziquantel can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Praziquantel can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Praziquantel can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Praziquantel can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Praziquantel can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Praziquantel can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Praziquantel can be increased when it is combined with Osimertinib.Approved
PalbociclibThe serum concentration of Praziquantel can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Praziquantel can be decreased when combined with Pantoprazole.Approved
Peginterferon alfa-2bThe serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Praziquantel can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Praziquantel can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Praziquantel can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PosaconazoleThe metabolism of Praziquantel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimaquineThe serum concentration of Praziquantel can be decreased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Praziquantel can be decreased when it is combined with Primidone.Approved, Vet Approved
RanolazineThe metabolism of Praziquantel can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe serum concentration of Praziquantel can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Praziquantel can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Praziquantel can be decreased when it is combined with Rifapentine.Approved
RitonavirThe metabolism of Praziquantel can be decreased when combined with Ritonavir.Approved, Investigational
RopiniroleThe metabolism of Praziquantel can be decreased when combined with Ropinirole.Approved, Investigational
SaquinavirThe metabolism of Praziquantel can be decreased when combined with Saquinavir.Approved, Investigational
SertralineThe metabolism of Praziquantel can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Praziquantel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Praziquantel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Praziquantel can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Praziquantel can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Praziquantel can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Praziquantel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TelaprevirThe metabolism of Praziquantel can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Praziquantel can be decreased when combined with Telithromycin.Approved
TenofovirThe metabolism of Praziquantel can be decreased when combined with Tenofovir.Approved, Investigational
TeriflunomideThe serum concentration of Praziquantel can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Praziquantel can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Praziquantel.Approved
TiclopidineThe metabolism of Praziquantel can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Praziquantel can be decreased when it is combined with Tocilizumab.Approved
TopiramateThe metabolism of Praziquantel can be decreased when combined with Topiramate.Approved
TranylcypromineThe metabolism of Praziquantel can be decreased when combined with Tranylcypromine.Approved
VemurafenibThe serum concentration of Praziquantel can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Praziquantel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Praziquantel can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Praziquantel can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Praziquantel can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
  • Take with food.
References
Synthesis ReferenceNot Available
General References
  1. Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008 Dec;21(6):659-67. doi: 10.1097/QCO.0b013e328318978f. [PubMed:18978535 ]
  2. McManus DP, Loukas A: Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008 Jan;21(1):225-42. doi: 10.1128/CMR.00046-07. [PubMed:18202444 ]
External Links
ATC CodesP02BA01
AHFS Codes
  • 08:08.00
PDB Entries
FDA labelDownload (152 KB)
MSDSDownload (72.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.974
Blood Brain Barrier+0.9939
Caco-2 permeable+0.5496
P-glycoprotein substrateSubstrate0.7237
P-glycoprotein inhibitor IInhibitor0.8052
P-glycoprotein inhibitor IINon-inhibitor0.9113
Renal organic cation transporterInhibitor0.5469
CYP450 2C9 substrateNon-substrate0.8505
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5805
CYP450 1A2 substrateInhibitor0.846
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5401
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9637
BiodegradationNot ready biodegradable0.9413
Rat acute toxicity2.0726 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8291
hERG inhibition (predictor II)Non-inhibitor0.5813
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral600 mg
Tablet, film coatedOral600 mg/1
Prices
Unit descriptionCostUnit
Biltricide 600 mg tablet14.57USD tablet
Praziquantel powder1.06USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point136 °CPhysProp
water solubility400 mg/LMERCK INDEX (1996)
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.381 mg/mLALOGPS
logP2.42ALOGPS
logP2.3ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)19.38ChemAxon
pKa (Strongest Basic)-0.22ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.62 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity88.79 m3·mol-1ChemAxon
Polarizability34.84 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTetrahydroisoquinolines
Sub ClassNot Available
Direct ParentTetrahydroisoquinolines
Alternative Parents
Substituents
  • Tetrahydroisoquinoline
  • N-alkylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Tertiary carboxylic acid amide
  • Cyclic alcohol
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

1. Schistosome calcium ion (Ca2+) channels
Kind
Group
Organism
Schistosoma
Pharmacological action
yes
Actions
other/unknown
References
  1. Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008 Dec;21(6):659-67. doi: 10.1097/QCO.0b013e328318978f. [PubMed:18978535 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23